Fresh analysis reveals that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who end traditional lifestyle programs.
Published data in a leading health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing these drugs need to be informed of the risk of quick rebound weight gain when the medication concludes," warns expert Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight within about one and a half years.
Analyzing Therapies
The analysis, which examined 37 of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods.
Researchers point out that people who shed pounds through diet and exercise usually experience a more gradual creep back—approximately 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Doctors believe the mode of action of the drugs explains the amplified weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels far above than normal could lead to the system to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating a significant risk."
An Ongoing Condition?
Health authorities advise the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Many experts contend that, given the high risk of weight regain, the therapy might need to be ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the findings "emphasize the long-term character of excess weight," akin to managing conditions like diabetes.
Patient Accounts
Individuals who have stopped the jabs describe a intense return of appetite.
"It felt as if a switch activating and I was suddenly ravenous," said an individual.
This difficulty is exacerbated if patients have not adopted sustainable lifestyle or habit changes during therapy.
Significant Use
Figures indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Use is greater among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, researchers caution that while these medications are effective tools for shedding pounds, they are not a standalone cure and long-term success relies on combined behavioural management.
